NOVEL THERAPY FOR PANCREATIC CANCERS, TARGETING MOLECULAR FOUNDATION
Dr Michael KC Lee,
Medical Oncologist,
Peter MacCallum Cancer Centre,
Melbourne, Australia
RESEARCHER PROFILE
Filmed in Melbourne, Australia | February 2026
Dr Michael Lee is an experienced medical oncologist, sub-specialising in gastrointestinal cancers and neuroendocrine tumours at the Peter MacCallum Cancer Centre.
He plays a key role in molecular tumour boards at VCCC Alliance (Victorian Comprehensive Cancer Centre) and MPCCC (Monash Partners Comprehensive Cancer Consortium), ensuring the accurate and effective use of precision medicine in cancer care across the state.
His care philosophy, embodied in his practice name, “Can-Therapy,” promotes a CAN-do approach to CANcer care: empowering patients to thrive beyond cancer through cutting-edge research and personalised, values-driven care. Beyond the clinic, he leads research as a clinician scientist, developing therapeutic strategies that target RNA processing – the molecular blueprint cancer hijacks to fuel its growth and resistance – by altering its sequence is like changing words in a sentence to redefine cancer’s trajectory.
Supported by Pancare Foundation, the Paul Dear Post Doctoral Fellowship and his industry collaboration, his work aims to revolutionise outcomes for patients with this aggressive cancer by targeting its molecular foundation.
He is a recognised expert in pancreatic cancer care, combining research insights with exceptional patient care, while also providing comprehensive treatment for all cancer types.
Source: Supplied
https://orcid.org/0000-0001-8075-3608
-
Dr Lisa Melton
RESEARCH IN SANFILIPPO
@ SANFILIPPO CHILDREN’S FOUNDATION
SYDNEY, NEW SOUTH WALES, AUSTRALIA -
Digital Biomarkers and AI for Optimal Diagnosis, Treatment, and Decision-Making
Associate Professor Johan Verjans is a clinician-scientist with a strong focus on cross-disciplinary translational research. In his role as Deputy Director at the Australian Institute for Machine Learning (AIML)—one of the world’s premier machine learning institutes, with over 200 researchers—and as Group Leader of Artificial Intelligence at the South Australian Health and Medical Research Institute (SAHMRI), he integrates his expertise in molecular medicine, clinical research, and advanced imaging with machine learning applications. This unique combination enables him to drive the translation of cutting-edge AI research into practical medical applications. He works with global teams from multinationals on AI problems.
-
Identification & characterisation of molecular drivers of therapeutic resistance
Professor Pieter Eichhorn is an internationally experienced cancer biologist and research leader whose career has been defined by high-impact contributions at the interface of functional genomics, translational oncology, and research infrastructure strategy.
He completed his PhD at the University of Newcastle upon Tyne, contributing to the cloning of the gene associated with Cornelia de Lange Syndrome, before undertaking postdoctoral training at the Netherlands Cancer Institute in the laboratory of René Bernards. There, he performed pioneering functional genetic screens that identified key regulators of oncogenesis and therapy resistance, including critical roles for the PI3K signalling pathway in resistance to targeted breast cancer therapies.
